Progress Of Bayer’s Postmarket Essure Study ‘Inadequate’ Says FDA
Nearly half of the women with the device are no longer participating
The US FDA labelled the progress of Bayer’s 522 postmarket study of its Essure birth control device, which was pulled off the market in 2018, as “inadequate” due to significant numbers of women dropping out.
